Vertex Buys Crinetics at a Discount, Betting on Hidden Value

Vertex is paying $8.8 billion for Crinetics—1.76 times peak sales, well below the 2–4x typical for rare-disease deals. That gap signals Vertex sees upside the market hasn't priced in: Crinetics' acromegaly drug Palsonify could generate more than the $5 billion peak-sales estimate. The valuation reflects discipline in a heated M&A environment, though it bets on execution.